Persistence of cervical high-risk human papillomavirus in women living with HIV in Denmark - the SHADE.
Adult
CD4 Lymphocyte Count
Cervix Uteri
/ pathology
Cohort Studies
Denmark
/ epidemiology
Female
Genotype
HIV
HIV Infections
/ complications
Humans
Middle Aged
Papillomaviridae
/ genetics
Papillomavirus Infections
/ complications
Registries
Risk Factors
Squamous Intraepithelial Lesions of the Cervix
/ complications
Uterine Cervical Neoplasms
/ complications
Cervical cancer
HPV genotype distribution
HPV persistence
High-risk HPV
Immunodeficiency
Women living with HIV
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
22 Aug 2019
22 Aug 2019
Historique:
received:
02
05
2019
accepted:
13
08
2019
entrez:
24
8
2019
pubmed:
24
8
2019
medline:
28
10
2019
Statut:
epublish
Résumé
Women living with HIV (WLWH) have high rates of persistent high-risk human papillomavirus (hrHPV) infections and cervical cancer. We aimed to assess the distribution of hrHPV genotypes, risk factors of type-specific hrHPV persistence, and high-grade squamous intraepithelial lesions or worse (≥HSIL) in WLWH in Denmark. From the prospective Study on HIV, cervical Abnormalities and infections in women in Denmark (SHADE) we identified WLWH with a positive hrHPV test during the study period; 2011-2014. HIV demographics were retrieved from the Danish HIV Cohort Study and pathology results from the The Danish Pathology Data Bank. Logistic regression was used to identify risk factors associated with persistent hrHPV infection (positivity of the same hrHPV type in two samples one-two years after the first hrHPV positive date) and ≥ HSIL. Of 71 WLWH, 31 (43.7%) had persistent hrHPV infection. Predominant hrHPV genotypes were HPV58, 52, 51, and 35 and most frequently observed persistent genotypes were HPV52, 33 and 31. CD4 < 350 cells/μL predicted genotype-specific hrHPV persistence (adjusted OR 4.36 (95%CI: 1.18-16.04)) and ≥ HSIL was predicted by prior AIDS (adjusted OR 8.55 (95% CI 1.21-60.28)). This prospective cohort study of well-treated WLWH in Denmark found a high rate of persistent hrHPV infections with predominantly non-16/18 hrHPV genotypes. CD4 count < 350 cells/μL predicted hrHPV persistence, while prior AIDS predicted ≥HSIL.
Sections du résumé
BACKGROUND
BACKGROUND
Women living with HIV (WLWH) have high rates of persistent high-risk human papillomavirus (hrHPV) infections and cervical cancer. We aimed to assess the distribution of hrHPV genotypes, risk factors of type-specific hrHPV persistence, and high-grade squamous intraepithelial lesions or worse (≥HSIL) in WLWH in Denmark.
METHODS
METHODS
From the prospective Study on HIV, cervical Abnormalities and infections in women in Denmark (SHADE) we identified WLWH with a positive hrHPV test during the study period; 2011-2014. HIV demographics were retrieved from the Danish HIV Cohort Study and pathology results from the The Danish Pathology Data Bank. Logistic regression was used to identify risk factors associated with persistent hrHPV infection (positivity of the same hrHPV type in two samples one-two years after the first hrHPV positive date) and ≥ HSIL.
RESULTS
RESULTS
Of 71 WLWH, 31 (43.7%) had persistent hrHPV infection. Predominant hrHPV genotypes were HPV58, 52, 51, and 35 and most frequently observed persistent genotypes were HPV52, 33 and 31. CD4 < 350 cells/μL predicted genotype-specific hrHPV persistence (adjusted OR 4.36 (95%CI: 1.18-16.04)) and ≥ HSIL was predicted by prior AIDS (adjusted OR 8.55 (95% CI 1.21-60.28)).
CONCLUSIONS
CONCLUSIONS
This prospective cohort study of well-treated WLWH in Denmark found a high rate of persistent hrHPV infections with predominantly non-16/18 hrHPV genotypes. CD4 count < 350 cells/μL predicted hrHPV persistence, while prior AIDS predicted ≥HSIL.
Identifiants
pubmed: 31438877
doi: 10.1186/s12879-019-4377-5
pii: 10.1186/s12879-019-4377-5
pmc: PMC6706931
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
740Subventions
Organisme : The Danish Cancer Society and the AIDS Foundation
ID : Not applicable
Organisme : The Aragon Foundation
ID : Not applicable
Organisme : The Foundation of Aase and Ejnar Danielsens
ID : Not applicable
Organisme : The Foundation of Anna and Preben Simonsen
ID : Not applicable
Références
J Infect Dis. 2001 Sep 15;184(6):682-90
pubmed: 11517428
JAMA. 2002 Apr 24;287(16):2114-9
pubmed: 11966386
Int J STD AIDS. 2003 Jun;14(6):417-25
pubmed: 12816671
Nat Rev Cancer. 2007 Jan;7(1):11-22
pubmed: 17186016
J Clin Virol. 2008 Nov;43(3):307-12
pubmed: 18786854
Int J Epidemiol. 2009 Oct;38(5):1202-6
pubmed: 18799495
J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):274-82
pubmed: 19387354
Clin Epidemiol. 2010 Aug 09;2:51-6
pubmed: 20865103
Scand J Public Health. 2011 Jul;39(7 Suppl):22-5
pubmed: 21775345
HIV Med. 2012 Jul;13(6):372-8
pubmed: 22257000
Int J Cancer. 2012 Nov 15;131(10):2349-59
pubmed: 22323075
Sex Transm Dis. 2012 Jul;39(7):501-3
pubmed: 22695317
BJOG. 2013 Jan;120(1):41-9
pubmed: 23121095
BMC Infect Dis. 2012 Nov 12;12:293
pubmed: 23140254
Vaccine. 2012 Nov 20;30 Suppl 5:F168-74
pubmed: 23199960
Vaccine. 2012 Nov 20;30 Suppl 5:F24-33
pubmed: 23199964
J Infect Dis. 2013 Jun 1;207(11):1723-9
pubmed: 23463709
BMC Infect Dis. 2013 Dec 01;13:564
pubmed: 24289532
Viral Immunol. 2014 Feb;27(1):20-5
pubmed: 24494969
PLoS One. 2014 Feb 05;9(2):e88323
pubmed: 24505474
BMC Infect Dis. 2014 Jul 26;14:413
pubmed: 25064473
MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30
pubmed: 25167164
Int J Cancer. 2015 Jul 1;137(1):193-203
pubmed: 25471319
Curr HIV/AIDS Rep. 2015 Mar;12(1):6-15
pubmed: 25644977
HIV Med. 2016 Jan;17(1):7-17
pubmed: 26058995
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Int J Cancer. 2016 Jan 15;138(2):361-8
pubmed: 26238558
Am J Obstet Gynecol. 2016 Apr;214(4):438-443
pubmed: 26519782
AIDS. 2016 Jan 28;30(3):425-33
pubmed: 26765936
Mem Inst Oswaldo Cruz. 2016 Feb;111(2):120-7
pubmed: 26872340
BMC Infect Dis. 2016 Feb 16;16:81
pubmed: 26880101
Acta Cytol. 2016;60(6):501-512
pubmed: 27806357
BMC Cancer. 2016 Nov 8;16(1):866
pubmed: 27821088
Ann Intern Med. 2016 Nov 15;165(10):749-750
pubmed: 27842400
Clin Infect Dis. 2017 May 1;64(9):1228-1235
pubmed: 28199532
Prev Med. 2017 May;98:15-20
pubmed: 28279257
Front Public Health. 2017 Jul 21;5:178
pubmed: 28785554
J Infect Dis. 2017 Aug 15;216(4):447-456
pubmed: 28931234
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:95-106
pubmed: 28958633
Lancet HIV. 2018 Jan;5(1):e45-e58
pubmed: 29107561
Lancet Infect Dis. 2018 Feb;18(2):198-206
pubmed: 29158102
AIDS. 2018 Mar 27;32(6):795-808
pubmed: 29369827
Obstet Gynecol. 2018 Sep;132(3):725-735
pubmed: 30095780
J Int AIDS Soc. 2018 Aug;21(8):e25165
pubmed: 30101434
PLoS One. 2018 Oct 24;13(10):e0206219
pubmed: 30356297